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ABSTRACT
Objective: The objective of this study was to develop extended release (ER) pellets of Bosentan, an endothelin receptor antagonist using fluid bed 
processor (coating).
Method: The ER drug pellets of Bosentan were prepared using fluid bed coating. These drug-loaded pellets were further coated with ethyl cellulose of 
two viscosity grades and Eudragit as rate controlling polymers individual and in combination, hypromellose as pore former and binder, acetyl tributyl 
citrate as plasticizer, and magnesium stearate as anti-adhering agent.
Results: The drug release was extended up to 24 h, and the drug release was mainly depends on the polymer type and polymer proportion. In vivo study 
of Bosentan, ER pellets were performed in healthy rabbits (New Zealand, White) of either sex weighing (3.0–3.3 kg) and were divided into two separate 
groups, each group consisting of 6 animals. Maximum plasma concentration (Cmax), maximum time (Tmax), area under the curve (AUC0-t), elimination rate 
constant (Kel), and half-life (T1/2) were studied for optimized formulation. Formulation was releasing the drug for a prolonged period of time.
Conclusion: By the above results, it was observed that the prepared pellets could release the drug for an extended period when compared with the 
conventional dosage form of Bosentan, optimized formulation was shown longer half-life and Cmax indicates its acceptability. Finally, ER pellets of 
Bosentan were prepared for the treatment of pulmonary artery hypertension by fluid bed processor.
Keywords: Bosentan, Pellets, EC, Eudragits, Prolonged release pellets.
INTRODUCTION
It is estimated that 40% or more of active substances being identified 
through combinatorial screening programs are poorly soluble in 
water [1]. Poor solubility is not only a problem for the formulation 
development and clinical testing; it is also an obstacle at the beginning 
when screening new compounds for pharmacological activity. There is 
a definite need for smart technological formulation approaches to make 
such poorly soluble drugs bioavailable [2].
Multi-particulate dosage forms (MPDFs) are receiving immense attention 
as alternative drug delivery systems for oral drug delivery even though 
single-unit dosage forms have been widely used for decades [3]. MPDFs 
offer advantages over conventional dosage forms such as (1) predictable, 
reproducible and short gastric residence time, (2) less inter and intra-
subject variability, and (3) improve bioavailability [4,5]. Pelletization is 
often called a size enlargement process that involves the production of 
agglomerates relatively with a narrow size range of 0.5 mm–2 mm [6,7] 
and they are called pellets. Pellets have free-flowing properties and 
low porosity of about 10%. Since their multi-particulate nature offers 
many important pharmacological as well as technological advantages 
over conventional single unit solid dosage form, these formulations are 
preferred over other solid dosage forms [8]. In the past two decades, 
pellets have established their position for many reasons [9].
 Pellets offer greater flexibility in pharmaceutical solid dosage form 
design and development. They flow freely and pack easily without 
significant difficulties, resulting in uniform and reproducible fill weight 
of capsules and tablets. Ethylcellulose, a hydrophobic polymer which 
has more controlled release properties and used in the preparation of 
many dosage forms. Therefore, in this study, it was used to extend the 
drug release [10,11].
Extendable drug delivery systems come under controlled drug delivery 
systems, which are used to extend the release rate of drugs over an 
extended rate of period [12,13].
Bosentan is an endothelin receptor antagonist (ERAs). Patients 
with PAH have elevated levels of endothelin, a potent blood vessel 
constrictor, in their plasma and lung tissue. Bosentan blocks the 
binding of its receptors, thereby negating endothelins deleterious 
effects. Its oral bioavailability is approximately 50%, and food does 
not affect its absorption. It is having a terminal elimination half-life 
of 5 h [14].
From the above information on Bosentan, it is essential to formulate 
extended release (ER) dosage forms with least side effects as it has 
the oral bioavailability 50%, it is essential to increase bioavailability, 
and the half-life also need to be prolonged to improve the patient 
compliance by reducing the frequency of administration. This drug is 
indicated for the pulmonary artery hypertension; a chronic condition 
requires prolonged drug release.
MATERIALS AND METHODS
Materials
Bosentan was obtained as a free sample from Aurobindo Pharma Ltd, 
Hyderabad. MCC spheres were obtained from Aurobindo Pharma, 
HPMC E5 was obtained from Colorcon Asia, Ethyl Cellulose, Eudragit 
of different grades, and Magnesium stearate were obtained from Tini 
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Pharma Pvt., Ltd. All other chemicals and reagents used in the study 
were of analytical grade.
Preparation methods
Method for estimation of Bosentan
High-performance liquid chromatography (HPLC) method for the 
estimation of Bosentan was used for routine analysis of Bosentan in 
its formulations such as drug content and in vitro dissolution and drug 
content uniformity.
Preparation of mobile phase
The mobile phase was prepared using phosphate buffer of pH 7.4 and 
Acetonitrile at a ratio of 40:60 (Buffer:acetonitrile).
Preparation of stock solution
Accurately weighed 100 mg of Bosentan was transferred into 100 ml 
volumetric flask and dissolved in few ml of mobile phase and then 
further diluted and make up the volume up to 100 ml with using same 
mobile phase.
Preparation of standard solutions
From the above stock solution, standard concentrations of 50, 100, 
and 150 µg/ml solutions and the samples were filtered through 0.45 µ 
Millipore filter. The samples were loaded into the Shimadzu HPLC 
System model No 1020 CHT with autosampler. A standard calibration 
curve was plotted using the standard peak areas versus concentration. 
The column used for the analysis is C-18, inspire, 250 × 4.6 × 5 µ. The 
detector wavelength was 265 nm. The peak is of Bosentan and was 
showed in Table 1, and the calibration curve as shown in Fig. 1.
Drug loading on MCC spheres
MCC spheres were loaded into the fluid bed processor [15-19], the 
process parameters were adjusted as per the machine setting. The 
MCC spheres then preheated to the required temperature as per the 
set parameters. The drug solution was then sprayed on to the spheres 
using the peristaltic pump. The process parameters were monitored 
and then adjusted as per the pellets fluidization and weight gain. The 
prepared pellets were then dried for 12 h in a hot air oven to remove 
the complete moisture.
ER coating solution on drug-loaded pellets was prepared using ethyl 
cellulose and Eudragit. The solvent used in polymer solution was IPA and 
MDC. Tributyl citrate was used as plasticizer. Initially, ethylcellulose was 
added to the IPA and MDC 30:70 RATIO. The solution was then stirred 
for 30 min then plasticizer was added to it finally talc and magnesium 
stearate was added and stirred to get the uniform dispersion. The 
prepared solution was sprayed on to the drug-loaded pellets.
ER coating on drug-loaded pellets:[20,21]
The drug-loaded pellets were loaded into fluid bed processor. The 
pellets were preheated up to 45°C. The inlet and exhaust temperatures 
were set as per the requirement. The polymer solution was then 
sprayed on to the drug-loaded pellets. The different ratio or percent of 
the polymer ethyl cellulose alone and in combination with Eudragits 
were prepared and loaded on to the pellets. The pellets were then dried 
in a tray dryer overnight for complete evaporation of the solvent. The 
formula for ER coating solution of different polymers individually and 
in combination on drug-loaded pellets was shown in Table 2.
Evaluation of ER pellets
In vitro dissolution studies
Dissolution studies for each prepared formulation were performed 
in a calibrated dissolution test apparatus (LABINDIA), equipped with 
paddles (USP apparatus II method). 900 ml of 0.1 N hydrochloric 
acid solution was used as a dissolution medium. The paddles were 
operated at 50 rpm, and the temperature was maintained at 37±0.5°C 
throughout the experiment. Dissolution samples were withdrawn from 
the apparatus at regular intervals, i.e., 1, 2, 3…up to 24 h and replaced 
with equal volume of dissolution medium to maintain the sink condition 
throughout the experiment. Samples were withdrawn at various time 
intervals were suitably diluted with same dissolution medium, and 
the amount of drug released was estimated by chromatographically at 
272 nm.
In vivo study design
In vivo study of Bosentan, ER pellets were performed in healthy rabbits 
(New Zealand, White) of either sex weighing (3.0–3.3 kg) were divided 
Table 1: Peak areas of the Bosentan




Table 2: ER coating on drug-loaded pellets using EC N 10, N50, and Eudragit
Ingredients ER coating on MCC Spheres Mg/Unit
CB1# CB2 CB3 CB4 CB5 CB6 CB7 CB8 CB9 CB10 CB11 CB12 CB13 CB14
Drug loaded pellets 128 128 128 128 128 128 128 128 128 128 128 128 128 128
Ethyl cellulose 10 cps 15 20 25 30 ** ** ** ** ** ** ** ** 30 30
Ethyl cellulose 50 cps ** ** ** ** 5 10 15 20 10 10 10 10 ** **
Eudragit NE30D ** ** ** ** ** ** ** ** 2.5 5 7.5 10 7.5 10
Talc 5 5 5 5 5 5 5 5 5 5 5 5 5 5
HPMC E 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Tributyl citrate 2 2 2 4 4 4 6 6 6 8 8 8 8 8
IPA Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs
MDC Qs Qs Qs Qs Qs Qs Qs Qs ** ** ** ** ** **
Water         Qs Qs Qs Qs Qs Qs
Th. Weight 156 161 166 168 146 151 158 163 157.5 162 164.5 167 184.5 187
CB# indicates coated Bosentan pellets. ER: Extended-release
Fig. 1: Calibration curve of Bosentan in 0.1 N hydrochloric acid
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into two separate groups, each group consisting of 6 animals. The first 
group received conventional beads of Bosentan (80 mg) and the second 
group received the microbeads of Bosentan contain 80 mg of Bosentan. 
The beads were put behind the tongue to avoid biting by rabbit. Food 
was withdrawn from the rabbits before 12 h of drug administration 
and until 24 h post dosing. All rabbits have free access to water during 
the study period. The Institute Animal Ethical Committee approved the 
study protocol. PROTOCOL NO: 012/MRIPS/CPCSEA-IAEC/HYD/2018.
Standard calibration curve
Preparation of standard solution 10 mg of Bosentan monohydrate 
was weighed accurately and transferred into 100 ml volumetric flask. 
Ensured to dissolve the un-dissolved portions of drug by sonicating and 
final volume was made with mobile phase. Aliquot of 1ml was taken 
and transferred into a 10 ml clean and dry volumetric flask, and it was 
diluted up to the mark with the same diluent (10 µg/ml). From this, 1 ml 
was taken and further diluted to 10 ml to get a concentration of 1 µg/ml.
Blood sampling
Blood samples were collected at 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 
24 h from marginal ear vein. Blood collected was centrifuged at 2000–
Fig. 2: In vitro drug release profile of formulation CB1-CB4 made 
with EC N10
Fig. 3: In vitro drug release profile of formulation CB5-CB8 made 
with EC N50
Fig. 4: In vitro drug release profile of formulation CB9-CB12 made 
with EC N50: Eudragit NE30D
Fig. 5: In vitro drug release profile of formulations CB13-CB14 
made with EC N10: Eudragit NE30D
Fig. 6: Standard calibration curve of Bosentan in rabbit plasma
Table 3: Standard calibration curve of Bosentan in rabbit 
plasma
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3000 rpm for 10 min (Remi Equipment, Mumbai, India). The plasma 
samples were stored at refrigerator condition (−20°C) until analysis. 
Safety was evaluated by monitoring adverse events and vital signs and 
through physical examination.
Analytical method and instrumentation
Analyses were performed on a Shimadzu Scientific Instruments (Kyoto, 
Japan) liquid chromatographic system composed of a LC-10AT pump, a 
SPD-10A UV detector, and an ODS C-18 column 4.6 mm×250 mm) oven 
25 μl Hamilton injection syringe.
Chromatographic conditions
The mobile phase consisted of acetonitrile and phosphate buffer (pH 4.6) 
in 80:20 ratio. Before analysis, the mobile phase was filtered through a 
0.22 μm filter (Sartorius, USA), and then degassed ultrasonically for 15 
min. The analysis was conducted at 25°C, flow-rate of 1.0 ml/min and 
detection wavelength at 273 nm.
Extraction procedure of Bosentan
Extraction of drug from plasma of New Zealand rabbits 250 µl of 
plasma containing varying amount of Bosentan monohydrate was 
taken into a Teflon lined cap centrifuging tube followed by addition 
of 50 µl of 2 µg/0.5 ml of etodolac [internal standard (I/S)] and 2 ml 
of acetonitrile. The mixture was vortexed for 2 min and centrifuged at 
3300 rpm speed until organic layer was separated. Organic layer was 
collected and filtered through 0.2 µm membrane filter. 20 µl of filtrate 
was injected into the analytical column, and the eluents were observed 
at 273 nm. The concentrations in the range of 0.1–5 µg/0.5 ml of plasma 
were prepared. The experiment was repeated for 5 times for all the 
concentrations.
RESULTS AND DISCUSSION
In vitro dissolution studies were performed for all prepared pellets 
to find out the drug release, drug release mechanisms and also to 
know the effect of concentration and proportion of polymers used for 
extending the drug release from the core of the formulations. Among all 
the formulations, CB12 formulation was selected as best or optimized 
formulation based on the drug release and its physical properties. The 
formulation CB12 was extended the drug release up to 24 h, and it 
was prepared with Ethylcellulose N 50 (ECN50) and Eudragit polymer. 
Results were showed in Figs. 2-5.
Standard calibration curve of Bosentan in rabbit plasma
Linearity was observed within the range of 0.1–1 µg/ml with correlation 
coefficient of 0.999 showed in Fig. 6 and the values were shown in 
Table 3. The retention time of Bosentan was found at 3.648 min and 
the retention time of the etodolac (I/S) was found at 4.132 min (Fig. 7).
Pharmacokinetic assessment
All the pharmacokinetic results were showed in Table 4. The plasma 
kinetic data were assessed with KINETIKA 5.0 software. Fig. 8 shows 
the mean comparative data plot of the mean plasma concentration of 
the Bosentan in both test (ER formulation) and reference (conventional 
formulation). The mean peak plasma concentration of test (T) 
formulation Cmax 3.412 µg/ml was gradually reached in 3.0 h. In case of 
conventional reference formulation (R), the Cmax was 5.074 µg/ml which 
was reached in 1.5 h. The concentration maximum of the test formulation 
(T) was lower when compared with reference (R) formulation. The 
increased Tmax was clearly indicates the drugs availiability for the 
longer duration. Tables show the kinetic data of Bosentan conventional 
formulation (R) and ER formulations (T), respectively.
The reference (R) formulation was absorbed rapidly, the Tmax reached 
in about 1.5 h. After reaching the Tmax, the drug starts rapid elimination 
and the concentration gradually reduced. In case of test (T) formulation, 
the Tmax achieved gradually, and the drug availability was long time.
The AUC0-t, of the reference (R) was found to be 7.312 µg min/ml, the 
increase in AUC0-t of around 10.421 µg min/ml was observed in the test 
(T) formulation, and this clearly indicates the drug availability for long 
period of time.
Decrease in elimination rate constant (Kel) from 0.181 h−1 (Reference) 
(R) to 0.093 h−1 (Test) indicates the lower release rate of drug in the 
body.
The half-life (T1/2) of the reference (R) and test (T) formulations were 
3.75 h and 7.45 h, respectively, which were significantly different. Thus, 
the prolonged T1/2 is another indication on the in vivo performance of 
the Bosentan ER beads.
The overall Cmax, Tmax, AUC0-t, Kel, and T1/2 were completely different 
between both test and reference formulation. Therefore, the prepared 
formulation was releasing the drug for a prolonged period of time.
CONCLUSION
A fluid bed coating method was successfully applied to make Bosentan 
prolonged-release pellets. Drug solution was loaded into the MCC 
spheres, and then the drug-loaded spheres were coated with ECN50, 
and Eudragit NE30D in different proportions of polymers were used 
Fig. 7: High-performance liquid chromatography chromatogram 
of Bosentan and Internal standard rabbit plasma 
Table 4: Pharmacokinetic data of Bosentan 80 mg immediate-release tablets (R)
Treatment Subjects Tmax Cmax AUC0-t AUC0‑∞ Kel T½
h µg/mL µg.h/mL µg.h/mL h-1 h
Reference (R)-IR 6 1.5 5.074 7.312 11.271 0.181 3.75
Test (T)-ER 6 3.0 3.412 10.421 15.121 0.093 7.45
Fig. 8: Comparative plasma profiles of Bosentan 80 mg 
conventional formulation (R) with Bosentan 80 mg ER Pellets 
formulation (T)
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among those formulation CB12 with 1:1 proportion of ECN50 and 
Eudragit was shown better drug release. The in vitro release profiles 
indicated that the release of Bosentan from the pellets exhibited a 
controlled release behavior. In vivo studies were conducted in New 
Zealand rabbits. Based on the results of in vivo study, the overall Cmax, 
Tmax, AUC0-t, Kel, and T1/2 were completely different between both test and 
reference formulation. Therefore, the ready formulation was releasing 
the drug for a prolonged period. Finally, the present work demonstrates 
the feasibility of controlled delivery of Bosentan utilizing MCC-based 
pellets.
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